Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Report Date: October 25, 2022
Reporting Period: Third Quarter 2022
This filing serves as a notification that the Company issued an Earnings Press Release and supplemental information regarding its financial results for the third quarter of 2022. The filing incorporates by reference the press release, supplemental data, and a presentation used during the earnings conference call held on October 26, 2022.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced exhibits (Exhibit 99.1, 99.2, and 99.3) which are incorporated by reference but not detailed in the body of this 8-K filing.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It directs investors to the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2) for a comparison of financial results and operating initiatives.
Guidance, Outlook, and Risks
- Management Commentary: The Company posted a presentation (Exhibit 99.3) on October 26, 2022, covering financial and operating initiatives. This presentation includes non-GAAP financial measures.
- Non-GAAP Measures: Reconciliations between non-GAAP and GAAP measures are available in the Supplemental Information (Exhibit 99.2).
- Legal Disclaimer: The information in Item 7.01 (Regulation FD Disclosure) and its associated exhibits is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities thereof, except as specifically provided in future filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.2 (Supplemental Information) for reconciliations of non-GAAP financial measures and detailed segment performance.
- Consult Exhibit 99.3 (Presentation Materials) for management's outlook, strategic initiatives, and forward-looking statements.
- Verify the availability of the presentation on the Company's website, as the Company reserves the right to discontinue access at any time.